

Bordetella

Friday, September 19, 2025 6:10 PM

✍ Bordetella pertussis (Whooping Cough)

⌚ Important Properties

- Morphology: Small, coccobacillary, encapsulated, Gram-negative rod.
- Host: Humans only.
- Transmission: Airborne droplets during severe coughing episodes.

✍ Pathogenesis & Epidemiology

- Attachment:
 - Binds to ciliated epithelial cells of the upper respiratory tract (does not invade tissue).
 - Mediated by filamentous hemagglutinin (FHA) on pili.
 - Antibody against FHA → blocks attachment → protection.

- Key Virulence Factors:

1. Pertussis toxin (A-B toxin)

- Catalyzes ADP-ribosylation of Gi protein → inhibits Gi → unopposed adenylate cyclase activity.
- ↑ cAMP → edema of respiratory mucosa → severe cough.
- Also causes lymphocytosis by preventing lymphocyte migration into lymphoid tissue.

2. Adenylate cyclase enzyme

- Produced by bacteria, taken up by neutrophils → inhibits phagocytosis.
- Mutants lacking cyclase activity = avirulent.

3. Tracheal cytotoxin

- Fragment of peptidoglycan.
- Damages ciliated epithelial cells.
- Acts with endotoxin to induce nitric oxide → kills cilia.

- Epidemiology:

- Primarily in infants & young children .
- Highly contagious.
- Declined due to vaccines but periodic outbreaks occur due to waning immunity.

- Flow of Pathogenesis

Inhalation of droplets

- Attachment to ciliated epithelium (via FHA)
- Pertussis toxin → ↑ cAMP → edema + lymphocytosis
 - Adenylate cyclase → ↓ neutrophil activity
 - Tracheal cytotoxin + endotoxin → ciliary death
 - Persistent severe cough (whooping cough)

- Clinical Findings

- Early phase: Mild upper respiratory tract infection.

- Paroxysmal phase (1-4 weeks):

- Severe paroxysmal cough → repeated hacking coughs + copious mucus.
- Followed by inspiratory "whoop" (due to narrowed

glottis).

- Leukocytosis: up to 70% lymphocytes.
- Organism remains localized to respiratory tract
→ blood cultures negative.

- Complications:

- CNS anoxia, exhaustion due to coughing.
- Pneumonia → main cause of death.

- Adults:

- "100-day cough" (chronic paroxysmal cough).
- Whoop often absent → underdiagnosed.

III Table: Clinical Course of Pertussis

Stage	Duration	Features
Catarrhal stage	1-2 weeks	Mild URTI, highly contagious
Paroxysmal stage	1-4 weeks	Severe coughing fits, inspiratory "whoop," mucus
Convalescent stage	Weeks-months	Gradual recovery, cough may persist



Laboratory Diagnosis

- Specimen: Nasopharyngeal swab (best during paroxysmal stage).
- Culture:
 - Medium: Bordet-Gengou agar (20-30% blood → inactivates inhibitors).
 - Growth: Slow → limits routine diagnosis.
- Identification:
 - Agglutination with specific antiserum.
 - Fluorescent antibody staining.
- Rapid Tests:
 - PCR → rapid, specific, highly sensitive .
 - Direct fluorescent antibody staining on swab.
- Serology: Antibody detection in patients with prolonged

cough.

- Limitation: Isolation difficult in late disease.

Flow of Diagnosis

Nasopharyngeal swab

→ Bordet-Gengou culture (slow) OR Fluorescent antibody staining

→ PCR (preferred, rapid & sensitive)

→ If prolonged cough → Serology for antibodies

Treatment

- Drug of choice: Azithromycin (a macrolide).
 - Reduces organisms in throat → ↓ transmission & complications.
 - Little effect once mucosal damage has occurred (prolonged cough stage).

- Supportive care (esp. in infants):

- Oxygen therapy
- Mucus suction

🛡 Prevention

I. Vaccines

- Acellular pertussis vaccine (aP) (currently used in US):

- ▶ Contains 5 antigens:

- Pertussis toxoid (genetically inactivated toxin)
 - Filamentous hemagglutinin (FHA)
 - Pertactin
 - Fimbriae types 2 & 3

- Advantages: Fewer side effects.
 - Disadvantage: Shorter duration of immunity.

- Killed whole-cell vaccine (no longer used in US):

- Still used in some countries.
 - Associated with side effects (rare encephalopathy)

≈ 1/million doses).

2. Immunization Schedule

- DTaP (Diphtheria, Tetanus, acellular Pertussis):
 - 3 primary doses beginning at 2 months.
 - Booster: 12–15 months.
 - Booster: At school entry.
- Adolescents: Booster (10–18 years) → Boostrix or Adacel (contain diphtheria & tetanus toxoids too).
- Adults: Pertussis booster recommended.
- Pregnant women: Should be vaccinated → maternal IgG crosses placenta → protects newborn .

3. Post-Exposure Prophylaxis

- Azithromycin:
 - For exposed, unimmunized individuals.
 - Also for exposed immunized children <4 years (since vaccine immunity is incomplete).

Table: Prevention Strategies for Pertussis

Strategy	Details
Vaccine	Acellular vaccine (aP) – 5 antigens
Schedule	Primary (2 mo), Booster (12–15 mo), School entry, Teen & adult boosters
Pregnant women	Vaccination → maternal IgG → protects newborn
Post-exposure	Azithromycin for exposed (unimmunized or partially immunized children)